Algeta ASA's IPO on the Oslo Stock Exchange hit the upper end of its target, raising gross proceeds of slightly less than NOK250 million (US$41.1 million). (BioWorld International)
Algeta ASA's IPO on the Oslo Stock Exchange hit the upper end of its target, raising gross proceeds of slightly less than NOK250 million (US$41.1 million). (BioWorld International)
Polish biotechnology firm Bioton SA continued its expansion into Western Europe by picking up Swiss biosimilar drug developer BioPartners Holdings AG in a stock-based deal valued at $77.8 million. That total includes $15.8 million in BioPartners debt, as well as 81.5 million Bioton shares, valued at around PLN183.4 million (US$62 million). (BioWorld International)
